Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium-177
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
Lutetium-177 is a radioactive isotope of the element lutetium used as the active component in several radiopharmaceuticals for targeted cancer therapy. It is most commonly found in drugs such as Lutathera (lutetium Lu 177 dotatate) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan). These agents are classified as peptide receptor radionuclide therapies (PRRT), delivering targeted beta radiation to tumor cells that express specific receptors. Lutathera is approved for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), while Pluvicto targets prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer. The mechanism involves binding to tumor cell surface receptors—such as somatostatin or PSMA—followed by internalization and localized emission of cytotoxic radiation that induces DNA damage and cell death[1][2][3][4][5][7].
- Brand names
- LutatheraPluvicto
- Other names
- lutetium Lu 177 dotatatelutetium Lu 177 vipivotide tetraxetanlutetium (177Lu) oxodotreotide177Lu-dotatate177Lu-PSMA-617
02
Targets
PSMA (Prostate-specific membrane antigen)SSTR2 (Somatostatin receptor type 2)SSTR (Somatostatin receptors)
Beyond the preview
Go deeper on lutetium-177.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium-177.